Everolimus in de Novo Kidney Transplant Recipients

PHASE3CompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Kidney Transplantation
Interventions
DRUG

Everolimus

Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.

DRUG

Mycophenolate sodium

Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.

DRUG

Cyclosporine

Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.

DRUG

Steroids

Steroids were administered according to local clinical practice.

Trial Locations (22)

20132

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

28100

Novartis Investigative Site, Novara

35128

Novartis Investigative Site, Padua

37126

Novartis Investigative Site, Verona

40138

Novartis Investigative Site, Bologna

41100

Novartis Investigative Site, Modena

50139

Novartis Investigative Site, Florence

53100

Novartis Investigative Site, Siena

60126

Novartis Investigative Site, Ancona

67100

Novartis Investigative Site, Coppito

70124

Novartis Investigative Site, Bari

84131

Novartis Investigative Site, Salerno

90127

Novartis Investigative Site, Palermo

95123

Novartis Investigative Site, Catania

09134

Novartis Investigative Site, Cagliari

00144

Novartis Investigative Site, Roma

00152

Novartis Investigative Site, Roma

00161

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY